
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp has demonstrated a robust 15% year-over-year increase in Healthcare/Life Sciences (HCLS) new program wins, amounting to $130 million, indicating strong demand and growth prospects in this key segment. The company's return on invested capital (ROIC) has improved to 13.8%, reflecting enhanced operational efficiency and profitability compared to the prior quarter. Furthermore, a significant turnaround in free cash flow, rising to $27 million from a negative $32 million a year ago, along with an increased FY25 outlook for free cash flow to $100 million, underscores the company's financial strength and positive operational trajectory.
Bears say
Plexus Corp reported a revenue decline of 1% year-over-year to $976 million, falling short of both guidance and market expectations. The company anticipates flat sequential revenue in the upcoming quarter, primarily due to significant weakness in its Industrial segment, which is projected to decline by high single to low double digits. Additionally, free cash flow sharply decreased to $27 million in the first quarter, down from $194 million in the previous quarter, indicating potential cash flow challenges ahead.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares